A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.
Renal Cell Carcinoma
BIOLOGICAL: CTX130
Part A (dose escalation): Incidence of adverse events, Adverse events defined as dose-limiting toxicities, From CTX130 infusion up to 28 days post-infusion|Part B (cohort expansion): Objective response rate, Objective response rate per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, From CTX130 infusion up to 60 months post-infusion]
Progression Free Survival, From date of CTX130 infusion until date of disease progression or death due to any cause, assessed up to 60 months|Overall Survival, From date of CTX130 until date of death due to any cause, assessed up to 60 months
The study may enroll approximately 107subjects in total.